TITLE

In Vivo Veritas: In Vitro Macrolide Resistance in Systemic Streptococcus pneumoniae Infections Does Result in Clinical Failure

AUTHOR(S)
Jacobs, Michael R.
PUB. DATE
September 2002
SOURCE
Clinical Infectious Diseases;9/1/2002, Vol. 35 Issue 5, p565
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Editorial. Comments on a research article by J.R. Lonks et al. which deals with the failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae, published in the volume 35, 2002 edition of the periodical 'Clinical Infectious Diseases.' Susceptibility of the causative agent to macrolides; Pharmacokinetic properties of macrolides.
ACCESSION #
7226688

 

Related Articles

  • Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin-Resistant. Lonks, John R.; Garau, Javier; Gomez, Lucia; Xercavins, Mariona; Ochoa de Echaguen, Anna; Gareen, Ilana F.; Reiss, Philip T.; Madeiros, Antone A. // Clinical Infectious Diseases;9/1/2002, Vol. 35 Issue 5, p556 

    The rate of macrolide resistance among Streptococcus pneumoniae is increasing, but some investigators have questioned its clinical relevance. We conducted a matched case-control study of patients with bacteremic pneumococcal infection at 4 hospitals to determine whether development of...

  • Clinical Relevance of Macrolide-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia. Lynch III, Joseph P.; Martinez, Fernando J. // Clinical Infectious Diseases;3/1/2002 Supplement 1, Vol. 34, pS27 

    Discusses the prevalence of macrolide resistance among Streptococcus pneumoniae, risk factors and mechanisms responsible for resistance, therapeutic strategies and implications for the future. Impact of antimicrobial resistance on clinical outcomes; Clinical significance of in vitro macrolide...

  • Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Fuller, J.; McGeer, A.; Low, D. // European Journal of Clinical Microbiology & Infectious Diseases;Dec2005, Vol. 24 Issue 12, p780 

    Community-acquired pneumonia is the most common infectious disease that causes death, with Streptococcus pneumoniae remaining the leading causative pathogen. The worldwide incidence of infections caused by pneumococci resistant to penicillin, macrolides, and other antimicrobial agents has...

  • Increase in Pneumococcus Macrolide Resistance, United States. Jenkins, Stephen G.; Farrell, David J. // Emerging Infectious Diseases;Aug2009, Vol. 15 Issue 8, p1260 

    During year 6 (2005-2006) of the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin surveillance study, 6,747 Streptococcus pneumoniae isolates were collected at 119 centers. The susceptibility of these isolates to macrolides was compared with data from...

  • Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Jenkins, Stephen G.; Brown, Steven D.; Farrell, David J. // Annals of Clinical Microbiology & Antimicrobials;2008, Vol. 7, Special section p1 

    Background: The increasing prevalence of resistance to established antibiotics among key bacterial respiratory tract pathogens, such as Streptococcus pneumoniae, is a major healthcare problem in the USA. The PROTEKT US study is a longitudinal surveillance study designed to monitor the...

  • The Decline of Pneumococcal Resistance after Cessation of Mass Antibiotic Distributions for Trachoma. Haug, Sara; Lakew, Takele; Habtemariam, Gabremaskal; Alemayehu, Wondu; Cevallos, Vicky; Zhaoxia Zhou; House, Jenafir; Ray, Kathryn; Porco, Travis; Rutar, Tina; Keenan, Jeremy; Lietman, Thomas M.; Gaynor, Bruce D. // Clinical Infectious Diseases;9/1/2010, Vol. 51 Issue 5, p571 

    After 6 biannual mass distributions of oral azithromycin for trachoma in Ethiopian communities, 76.8% (95% confidence interval [CI], 66.3%-85.1%) of nasopharyngeal Streptococcus pneumoniae isolates from children aged 1-5 years were resistant to macrolides. Twelve and 24 months after the last...

  • Macrolides resistance rising. Andresen, Margot // CMAJ: Canadian Medical Association Journal;1/16/2007, Vol. 176 Issue 2, p159 

    The article reports that the antibiotics recommended by the Canadian guidelines for the treatment of pneumonia had failed due to increased resistance by Streptococcus bacteria. Donald Low, chief microbiologist in a Toronto hospital, stated that persons taking long acting macrolides had 30-50%...

  • Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. Wierzbowski, Aleksandra K.; Karlowsky, James A.; Adam, Heather J.; Nichol, Kim A.; Hoban, Daryl J.; Zhanel, George G. // Journal of Antimicrobial Chemotherapy (JAC);Jan2014, Vol. 69 Issue 1, p59 

    Objectives Studies were performed to assess resistance mechanisms, multidrug resistance (MDR), genetic relatedness, serotype distribution, heptavalent pneumococcal conjugate vaccine (PCV7) coverage and pili virulence factors among macrolide-resistant Streptococcus pneumoniae (MRSP) isolated from...

  • Appropriate Use of Antimicrobials for Drug-Resistant Pneumonia: Focus on the Significance of b -Lactam--Resistant Streptococcus pneumoniae. File Jr., Thomas M. // Clinical Infectious Diseases;3/1/2002 Supplement 1, Vol. 34, pS17 

    Discusses the clinical significance of penicillin-resistant Streptococcus pneumoniae. Background of the emergence of resistant S. pneumoniae; Pharmocodynamic considerations and treatment guidelines; Challenges associated with choosing empirical antimicrobials in the era of increasing drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics